Loading...
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea
Hydroxyurea (HU) has traditionally been the first-line treatment for patients with PV or ET at high-risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistance is associated with disease...
Na minha lista:
| Udgivet i: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4835800/ https://ncbi.nlm.nih.gov/pubmed/24524340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.893310 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|